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359 Use of radiological tools in French cystic ﬁbrosis centers:
A national survey
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d’Imagerie’ de la Socie´te´ Franc¸aise de la Mucoviscidose. 1Centre de Re´fe´rence
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Hoˆpital Robert Debre´, Paris, France
Radiological tools are critical for monitoring cystic ﬁbrosis (CF) patients’ thoracic,
abdominal, rhinosinusal, and bone systems. Given the likelihood of increasing
demand for ionizing techniques for research purposes, we sought to determine
how clinicians use radiological tools in their centers.
Methods: A 39-item questionnaire was sent to 49 pediatric and adult CF centers
in July 2011. Questions were asked on frequency and indications for thoracic,
abdominal, rhinosinusal, and bone imaging, as well as the radiological devices
available.
Results: Thirty-three of 49 (68%) centers answered the questionnaire. Among them,
36% were pediatric centers, 33% mixed, and 31% adult centers. An annual chest
x-ray was done routinely in more than 95% of centers, starting at the initial stage of
the disease (neonatal screening). While adult clinicians did not routinely perform
chest CT, 72% of the pediatricians requested it routinely. Pediatricians declared
doing the ﬁrst chest CT at a mean of 4.9±1.2 years of age, and every 2 or 3 years
thereafter. Respectively, 32% and 20% of pediatric and adult centers regularly
indicated the cumulative doses received by patients on medical charts. MRI was
used in seven out of 33 centers mainly for abdominal indications.
Annual chest x-ray is part of routine follow-up for most centers; however, divergent
attitudes have emerged regarding chest CT use between pediatric and adult centers.
The reasons for the routine use of chest CT in pediatric patients will need further
investigations. Furthermore, efforts should be made by clinicians to regularly
monitored cumulative doses received by their patients, particularly in the pediatric
population.
360 Clinical evolution of cystic ﬁbrosis in 20 years: Experience at a
referral center
F.A. Marson1,2, C.S. Bertuzzo1, A.F. Ribeiro2, J.D. Ribeiro2. 1Unicamp, Genetics,
Campinas, Brazil; 2Unicamp, Pediatrics, Campinas, Brazil
Objectives: To evaluate and compare the clinical outcome of Cystic Fibrosis (CF)
patients in the last 20 years at a referral center between 1990–2000 and 2000–2010.
Methods: Cross-sectional study with 181 patients. Mean, median and standard
deviation for continuous variables and absolute frequency for discrete variables were
used. Programs: SPSS v.17.0. Statistical power above 80%, a=0.05. Variables: sex,
ethnicity, deaths, inbreeding, manifestations (respiratory/digestive), clinical onset,
patient age, diagnosis age, comorbidities [diabetes (DM) and meconium ileus (MI)],
nutritional status, SaO2, microorganisms [(S. aureus, P. aeruginosa mucoid (PAM)
and non-mucoid (PANM), B. cepacia (BC)], spirometry, F508del, Shwachman-
Kulczycki (SK) and fat balance. The respiratory and digestive clinical manifes-
tations show a highest incidence: presence of pancreatic insufﬁciency (p = 0.031),
MI (p = 0.021), DM (p = 0.001) and BC (p = 0.016). There was a reduction in the
excellent and good SK, and increasing of moderate and severe (p = 0.005). For
F508del mutation, there was an increase in patients without the mutant allele and
reduction in the heterozygous (p< 0.001). Reduction was observed in the number
of patients: below the 10th percentile for weight (p< 0.001) and height (p = 0.025),
with PAM (p = 0.001) and PANM in the same time (p< 0.001). In spirometry, there
was an increase of restrictive ventilatory defect and reduction in obstructive and
mixed (p< 0.001). There was a reduction diagnosis time for CF.
Conclusion: In the last 10 years there have been changes in the clinical presentation
of patients due to early diagnosis, along with the best outpatient care and treatment.
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Objectives: Evaluate the clinical, genetic, microbiological and functional features
of cystic ﬁbrosis patients, registered in the Moscow region until January 2011.
Methods: A retrospective analysis of 359 patients registration cards (183 men/
176 women) with a conﬁrmed cystic ﬁbrosis diagnosis. Statistical processing using
SPSS (SPSS Inc., Chicago, IL).
Conclusion: The average age was 12.1±9.6 years (0.2–43.2 y), median − 11.0
(16.0) years. The adults percent (>18 years) − 30.6%. The median age of diagnosis
was 1.0 (5.0) y, 3.8% of the total number of patients (12.4% of adults) the diagnosis
is made in adulthood. The frequency of the most common mutation in the world
F508del was 52.96%, marked quite high proportion of “soft” genotypes of adult
patients. The high proportion of infection with Burkholderia cepacia complex −
8.7% − was noted while microbiological monitoring. There was a signiﬁcant
increase with age, the incidence of pneumothorax, hemoptysis, hypoxemic res-
piratory failure and diabetes with fasting hyperglycemia, while the incidence of
liver cirrhosis with portal hypertension between groups of adults and children is
comparable.
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Objectives: To describe the new beginning and the evolution of the Brazilian Cystic
Fibrosis Registry (REBRAFC).
Methods: Initial conversations to restart the Brazilian CF registry occurred in 2007.
The initiative was fully supported by the Brazilian Cystic Fibrosis Study Group
(GBEFC). The modeling and project of the Web system used methods based on
Uniﬁed Modeling Language (UML). Free and open software were adopted for
programming, and the security of the system was planned in several layers using
interceptions provided by the Struts2 framework. The main contents of the registry
were Demographics, Diagnosis data and Clinical data. This last item would be
inserted annually, including number of consultations, nutritional and functional
data, current treatments, microbiology data and Schwachman-Kulczycki score.
Identiﬁcation of patients is protected. A formal disclosure contract was celebrated
between the GBEFC and each Center. The ﬁrst Annual Patient Registry Report
(2009) was published in 2011 and the second one (2010) has just been published.
A signiﬁcant increase in the number of patients included (43.6%) and annual follow-
ups (45%) was noticed during this period. Several adjusts in the Web-based platform
to limit data values and minimize errors have also been done with success. Some
Brazilian States, however, are still not well represented due to local problems/lack
of interest.
Conclusion: The new Brazilian CF Registry is fully operational and expanding
signiﬁcantly, but new strategies to improve insertion are needed.
